Upcoming Events

Year: 2019

Latest news

IIBB researchers identify BCL-xL as a key protein in hepatocellular carcinoma (HCC) resistance to regorafenib treatment.

A recent article in the journal CANCERS with Blanca Cucarull and Anna Tutusaus as the first authors, from the Signaling in Cell Damage and Cancer group, and led by Albert Morales, identifies reduced levels of BCL-xL/MCL-1 as a marker of efficacy of anti-tumor therapy with regora

Read More